BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 25895135)

  • 1. Cost-effectiveness of digital mammography screening before the age of 50 in The Netherlands.
    Sankatsing VD; Heijnsdijk EA; van Luijt PA; van Ravesteyn NT; Fracheboud J; de Koning HJ
    Int J Cancer; 2015 Oct; 137(8):1990-9. PubMed ID: 25895135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
    Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
    Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratification in breast cancer screening: Cost-effectiveness and harm-benefit ratios for low-risk and high-risk women.
    Sankatsing VDV; van Ravesteyn NT; Heijnsdijk EAM; Broeders MJM; de Koning HJ
    Int J Cancer; 2020 Dec; 147(11):3059-3067. PubMed ID: 32484237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Program-specific cost-effectiveness analysis: breast cancer screening policies for a safety-net program.
    Melnikow J; Tancredi DJ; Yang Z; Ritley D; Jiang Y; Slee C; Popova S; Rylett P; Knutson K; Smalley S
    Value Health; 2013; 16(6):932-41. PubMed ID: 24041343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density.
    Pataky R; Ismail Z; Coldman AJ; Elwood M; Gelmon K; Hedden L; Hislop G; Kan L; McCoy B; Olivotto IA; Peacock S
    J Med Screen; 2014 Dec; 21(4):180-8. PubMed ID: 25186116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening.
    Koleva-Kolarova RG; Daszczuk AM; de Jonge C; Abu Hantash MK; Zhan ZZ; Postema EJ; Feenstra TL; Pijnappel RM; Greuter MJW; de Bock GH
    Maturitas; 2018 Mar; 109():81-88. PubMed ID: 29452787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Digital Breast Tomosynthesis in Population-based Breast Cancer Screening: A Probabilistic Sensitivity Analysis.
    Sankatsing VDV; Juraniec K; Grimm SE; Joore MA; Pijnappel RM; de Koning HJ; van Ravesteyn NT
    Radiology; 2020 Oct; 297(1):40-48. PubMed ID: 32749212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of digital breast tomosynthesis in a population breast cancer screening program.
    Wang J; Phi XA; Greuter MJW; Daszczuk AM; Feenstra TL; Pijnappel RM; Vermeulen KM; Buls N; Houssami N; Lu W; de Bock GH
    Eur Radiol; 2020 Oct; 30(10):5437-5445. PubMed ID: 32382844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Long-Term Effectiveness and Cost Effectiveness of Organized versus Opportunistic Screening for Breast Cancer in Austria.
    Schiller-Fruehwirth I; Jahn B; Einzinger P; Zauner G; Urach C; Siebert U
    Value Health; 2017 Sep; 20(8):1048-1057. PubMed ID: 28964436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women.
    Tina Shih YC; Dong W; Xu Y; Shen Y
    Value Health; 2019 Feb; 22(2):185-193. PubMed ID: 30711063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.
    Trentham-Dietz A; Kerlikowske K; Stout NK; Miglioretti DL; Schechter CB; Ergun MA; van den Broek JJ; Alagoz O; Sprague BL; van Ravesteyn NT; Near AM; Gangnon RE; Hampton JM; Chandler Y; de Koning HJ; Mandelblatt JS; Tosteson AN;
    Ann Intern Med; 2016 Nov; 165(10):700-712. PubMed ID: 27548583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness Analysis of Breast Cancer Screening Using Mammography in Singapore: A Modeling Study.
    Chootipongchaivat S; Wong XY; Ten Haaf K; Hartman M; Tan KB; van Ravesteyn NT; Wee HL
    Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):653-660. PubMed ID: 33531436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.
    Mandelblatt JS; Stout NK; Schechter CB; van den Broek JJ; Miglioretti DL; Krapcho M; Trentham-Dietz A; Munoz D; Lee SJ; Berry DA; van Ravesteyn NT; Alagoz O; Kerlikowske K; Tosteson AN; Near AM; Hoeffken A; Chang Y; Heijnsdijk EA; Chisholm G; Huang X; Huang H; Ergun MA; Gangnon R; Sprague BL; Plevritis S; Feuer E; de Koning HJ; Cronin KA
    Ann Intern Med; 2016 Feb; 164(4):215-25. PubMed ID: 26756606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dutch digital breast cancer screening: implications for breast cancer care.
    Timmers JM; den Heeten GJ; Adang EM; Otten JD; Verbeek AL; Broeders MJ
    Eur J Public Health; 2012 Dec; 22(6):925-9. PubMed ID: 22158996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study.
    Miglioretti DL; Lange J; van den Broek JJ; Lee CI; van Ravesteyn NT; Ritley D; Kerlikowske K; Fenton JJ; Melnikow J; de Koning HJ; Hubbard RA
    Ann Intern Med; 2016 Feb; 164(4):205-14. PubMed ID: 26756460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of mammographic screening strategies.
    Lindfors KK; Rosenquist CJ
    JAMA; 1995 Sep; 274(11):881-4. PubMed ID: 7674501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.
    Sprague BL; Stout NK; Schechter C; van Ravesteyn NT; Cevik M; Alagoz O; Lee CI; van den Broek JJ; Miglioretti DL; Mandelblatt JS; de Koning HJ; Kerlikowske K; Lehman CD; Tosteson AN
    Ann Intern Med; 2015 Feb; 162(3):157-66. PubMed ID: 25486550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition from film to digital mammography: impact for breast cancer screening through the national breast and cervical cancer early detection program.
    van Ravesteyn NT; van Lier L; Schechter CB; Ekwueme DU; Royalty J; Miller JW; Near AM; Cronin KA; Heijnsdijk EA; Mandelblatt JS; de Koning HJ
    Am J Prev Med; 2015 May; 48(5):535-42. PubMed ID: 25891052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.